Chober, D.; Aksak-Wąs, B.; Niścigorska-Olsen, J.; Niekrasz, M.; Parczewski, M.
Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study. Biomedicines 2022, 10, 1581.
https://doi.org/10.3390/biomedicines10071581
AMA Style
Chober D, Aksak-Wąs B, Niścigorska-Olsen J, Niekrasz M, Parczewski M.
Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study. Biomedicines. 2022; 10(7):1581.
https://doi.org/10.3390/biomedicines10071581
Chicago/Turabian Style
Chober, Daniel, Bogusz Aksak-Wąs, Jolanta Niścigorska-Olsen, Małgorzata Niekrasz, and Miłosz Parczewski.
2022. "Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study" Biomedicines 10, no. 7: 1581.
https://doi.org/10.3390/biomedicines10071581
APA Style
Chober, D., Aksak-Wąs, B., Niścigorska-Olsen, J., Niekrasz, M., & Parczewski, M.
(2022). Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study. Biomedicines, 10(7), 1581.
https://doi.org/10.3390/biomedicines10071581